Chronic Chikungunya Arthritis: NSAIDs or Early Methotrexate
Five months after acute chikungunya infection, a returning traveler's symmetric small-joint polyarthritis hasn't resolved and mimics early rheumatoid arthritis. The disagreement is whether a rheumatoid-like pattern this far out from infection has earned disease-modifying therapy, or whether the honest natural history still favors waiting it out.
Grace O., a 41-year-old woman, spent six weeks visiting her extended family abroad this past year, a trip she takes most years and had been looking forward to for the calligraphy lessons her aunt had promised to finally teach her. Ten days before she was due to fly home, she developed high fever, a diffuse rash, and joint pain severe enough that she could barely hold a pen — acute chikungunya infection, confirmed by positive IgM serology at a local clinic and later corroborated by IgG seroconversion after she returned. The fever and rash resolved within ten days, as expected, but the joint pain never fully went away.
Five months later, she still has symmetric, painful swelling of her wrists, second and third MCP joints, and both ankles, with morning stiffness lasting well over an hour — a pattern that, on exam alone, would be hard to distinguish from early rheumatoid arthritis. She was previously healthy, with no personal or family history of inflammatory arthritis before this trip. Rheumatoid factor and anti-CCP antibody are both negative, checked twice a month apart, which argues against a fresh case of seropositive RA emerging independently rather than confirming that what she has is simply chikungunya's own long tail. Her ESR and CRP are both mildly elevated, well below what her joint count and stiffness duration might suggest, and there is no radiographic erosion on plain films of her hands.
The functional cost is real and specific: the calligraphy she'd finally started learning is now essentially impossible some mornings, and she's had to leave two work reports unfinished because typing became too painful by midafternoon. Her tender and swollen joint counts today — eleven tender, seven swollen, symmetric and small-joint predominant — sit in a range that, on pattern alone, most rheumatologists would already be treating as early RA rather than continuing to watch. Ravindran and Alias's randomized trial of DMARD therapy in chronic chikungunya arthritis found that triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine reduced disease activity over twenty-four weeks far more than hydroxychloroquine monotherapy, which barely moved — evidence that a genuine subset of chikungunya-associated arthritis behaves, and responds, like a real inflammatory arthritis rather than a self-limited viral aftereffect. Two features of that trial cut against reading it straight onto her, though: every patient enrolled had been arthritic for more than a year before randomization, where she is at five months, and every patient was already established on hydroxychloroquine, so it never tested starting the drug in someone who had not had it. What it does establish, awkwardly for the most cautious option on the table today, is that hydroxychloroquine on its own was the arm that failed.
Follow-up visit, five months after acute illness
I'd start methotrexate today. She has symmetric small-joint synovitis, over an hour of morning stiffness, and five months of functional impairment that's already cost her work and the one hobby she came back from this trip most wanting to keep doing. Ravindran and Alias's randomized trial in chronic chikungunya arthritis found that triple DMARD therapy — methotrexate, sulfasalazine, and hydroxychloroquine together — reduced disease activity over twenty-four weeks far more than hydroxychloroquine monotherapy, which barely shifted at all. That's real evidence a genuine subset of this disease behaves like an inflammatory arthritis that responds to exactly the drugs we'd use for one — and it's evidence the antimalarial alone is not what does the work.
I don't doubt the trial data you're citing, but it was conducted in patients already selected for combination therapy, not in a comparison against simply waiting longer. Published natural-history cohorts following chikungunya arthritis over a year or more consistently find a majority of even chronic-phase cases resolve without ever starting a DMARD. Five months is genuinely uncomfortable to sit with, but it isn't outside that window.
Your trial evidence tells us DMARD therapy works once someone's already been started on it. It doesn't tell us whether starting it at five months, specifically, changes her outcome versus starting it at seven or eight if she isn't better by then — and that's the actual comparison this decision needs, not the one the trial answers.
There's a step in between that I don't think either of you is wrong to skip past, but I'd take it first: start hydroxychloroquine rather than methotrexate. And I'll name the obvious problem with that before either of you does — in the one randomized trial we have in this disease, hydroxychloroquine alone is the arm that lost. What I'd hold onto is who was in that arm: patients a year or more into their arthritis, all of them already taking hydroxychloroquine and still active on it. That is a group that had already demonstrated the drug wasn't working for them. She is five months out and has never taken it. Failing on an antimalarial and never having tried one are not the same finding, and the trial only measured the first. She doesn't meet formal RA classification criteria today, a real chance of spontaneous resolution remains, and hydroxychloroquine has a materially more benign long-term profile than methotrexate. If she isn't meaningfully better in two months, escalating then loses very little compared to starting methotrexate today.
Agreed: start hydroxychloroquine today rather than continuing NSAID-only management or moving directly to methotrexate, given her significant functional impairment weighed against her not yet meeting formal RA classification criteria. Naproxen continues for breakthrough symptoms. Reassess at eight weeks with a formal joint count and repeat inflammatory markers.
If she isn't meaningfully better at that visit, the group agreed in advance to escalate to methotrexate rather than extend a second empiric trial of hydroxychloroquine — not treated as a failure of today's plan, but as the threshold decided on before anyone knew which way her course would go.